ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1500 participants.

Also called NCT07687056

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,500 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07687056
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Canada (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07687056. Randomized; single masking; primary purpose treatment. Start 2026-08-11 (actual); primary completion 2030-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
ACT-GLOBAL IA Thrombolysis(ACT-REACT-004)Domain Within the ACT-GLOBAL Adaptive Platform Trial-NCT06352632
Acronym
ACT-REACT
Condition
Stroke, Acute Ischemic
Condition
Endovascular Thrombectomy
Condition
Acute Ischemic Stroke AIS
Intervention (Biological)
Tenecteplase or Alteplase- depending upon availability at each treating centre
Intervention (Other)
Control
Lead sponsor
University of Calgary (class: other)
Collaborator
The George Institute for Global Health, Australia (class: other)

Record details

Record id
cardio:ct-nct07687056
Content hash
b172ce90a020c5c3616f7035b7c5b8c49dfafd88dc969a811ae1053c738fe968